Colon-Targeted Oral Drug Delivery Systems

Oral drug delivery to the colon has long been recognised to have a multitude of challenges. Traditionally, targeting drugs to this region of the gastro-intestinal (GI) tract was viewed as a niche application, innately providing clinical benefits for localised diseases such as inflammatory bowel disease (IBD) or colorectal cancer.

However, as rapidly advancing techniques in molecular biology and medical imaging have increased our knowledge of human GI physiology, the colon has emerged as an optimal site for delivery of small molecules and biopharmaceuticals.

Evidently, the colon can serve as a favourable site of absorption and provide a valuable pathway for entering the systemic circulation. The emergence of evolutionary new scientific fields including microbiome therapeutics and chronotherapeutics bring promise of a new era of pharmacotherapy via the gut.

To help realise these opportunities, Intract Pharma has developed Phloral®, a dual-action technology enabling fail-safe delivery to the colon in both healthy and diseased states, and Soteria®, a revolutionary technology that transforms injectable biologics into oral pills.

Soteria

Soteria® is a revolutionary new technology that allows patients to take biopharmaceutical drugs, including monoclonal antibodies, as a simple and safe tablet or capsule.

Phloral

Phloral® is a cutting-edge technology for precise and consistent delivery to the colon. It exploits changes in gastrointestinal pH in combination with the enzymatic activity of the microbiota as independent but complementary release mechanisms to guarantee site-specific release.

Featured News

Intract’s Soteria® and Phloral® Technologies Highlighted Among Revolutionary Approaches to Crack Oral Biologics Delivery Challenge

Carus Animal Health and Intract Pharma Enter Agreement to Develop Novel Drug Delivery Technology

Intract Pharma Limited and Neopharma Japan Enter into a Collaboration to Develop a Novel Treatment for Gastrointestinal Diseases using Intract’s Proprietary Drug Delivery Technologies